

Index

Note: Page numbers of article titles are in **boldface** type.

A

- Acid(s), fatty, omega-3. See *Omega-3 fatty acids*.
- Altered oxidative phosphorylation (ATP) production, mitochondrial dysfunction in sepsis and, 572–573
- ARG1. See *Arginase 1 (ARG1)*.
- Arginase 1 (ARG1), depletion of, myeloid cells after, 495–496
- Arginine
 - deficiency of
 - after PI, 492
 - biologic function effects of, 492–495
 - depletion of
 - MDSC in correction of, 496–497
 - myeloid cells after, 495–496
 - dietary supplementation of, clinical studies of, 497–498
- Arginine deficiency syndrome, 498
- Aspiration, GRVs and, in critical illness, 485–486
- ATP production. See *Altered oxidative phosphorylation (ATP) production*.

B

- Biologic functions, arginine deficiency effects on, 492–495

C

- Cellular metabolism/apoptosis, GLN in, 517
- Cellular-organ protection, GLN in, 516–517
- Clinical guidelines, described, 451
- Critical illness
 - energy expenditure during, variations in, 444
 - fish oil in, **501–514**
 - GLN in, **515–525**. See also *Glutamine (GLN), in critical illness*.
 - GRVs in, **481–490**. See also *Gastric residual volumes (GRVs), in critical illness*.
 - gut protection in, **549–565**
 - omega-3 fatty acids in, **501–514**. See also *Omega-3 fatty acids*.
 - PN in, outcome effects of, **467–480**. See also *Parenteral nutrition (PN), in critical illness, outcome effects of*.
- Cytopathic hypoxia, microvascular dysfunction vs., mitochondrial dysfunction in sepsis and, 571

E

- EBM. See *Evidence-based medicine (EBM)*.
- EGF. See *Epidermal growth factor (EGF)*.
- EN. See *Enteral nutrition (EN)*.
- Energy expenditure, during critical illness

Energy expenditure (*continued*)

- modifications of, described, 446–447
- variations in, 444

Energy production, mitochondrial function and, 568–570

Enhanced recovery after surgery (ERAS), **527–547**

- components of, 529, 537
- cost-effectiveness of, 538
- described, 527–528
- history of, 528–537
- implementation of, problems and solutions related to, 538–540
- intraoperative recommendations, 532
- laparoscopy in, 537–538
- philosophy of, 528–537
- postoperative recommendations, 534–535
- preoperative recommendations, 530–531

Enteral nutrition (EN)

- after obtaining high volume of GRV, adverse effects of, 486–487
- gastric residual volumes tolerance on, effects of protocols for, SCCM/A.S.P.E.N. guidelines for, 455

Epidermal growth factor (EGF), in intestinal epithelial repair, regulation of, 551–553

ERAS. See *Enhanced recovery after surgery (ERAS)*.

Evidence-based medicine (EBM), SCCM/A.S.P.E.N. guidelines reliance on, 460–462

F

Fatty acids, omega-3. See *Omega-3 fatty acids*.

Fish oil

- in critical illness, **501–514**
- described, 501–502
- safety of, SCCM/A.S.P.E.N. guidelines for, 457–458

G

Gastric emptying, “poor man’s test” for, GRVs as, 487

Gastric residual volumes (GRVs), in critical illness, **481–490**

- as inexpensive “poor man’s test” for gastric emptying and tolerance of EN, 487
- aspiration and, correlation between, 485–486
- described, 481–482
- distinguishing between normal and abnormal gastric emptying, 483–484
- EN after obtaining high volume of, effects of, 486–487
- interpretation of, 484–485
- reliability and accuracy of, 483
- well standardized use of, 482–483

Gastrointestinal tract, mucosal repair in, 550–551

GLN. See *Glutamine (GLN)*.

GLP-2. See *Glucagon-like peptide 2 (GLP-2)*.

Glucagon-like peptide 2 (GLP-2), in intestinal epithelial repair, regulation of, 556

Glutamine (GLN), in critical illness, **515–525**

- cellular metabolism/apoptosis and, 517
- clinical outcome related to, 518
- effects on infectious complications, 520

- head injuries, 518
 - immune function and, 517–518
 - in cellular-organ protection, 516–517
 - in insulin resistance and hyperglycemia, 518
 - inflammatory response and, 517
 - length-of-stay effects of, 521
 - mechanisms of protection with, 516–518
 - mortality effects of, 519, 522
- Growth factors. See also specific types, e.g., *Epidermal growth factor (EGF)*.
- in intestinal epithelial repair
 - regulation of, 551–557
 - EGF, 551–553
 - GLP-2, 556
 - HB-EGF, 555–556
 - HGF, 555
 - IGF-1, 553–554
 - KGF, 554–555
 - TFF, 556–577
 - synergism between, 557
- GRVs. See *Gastric residual volumes (GRVs)*.
- Gut, protection of, in critical illness, **549–565**
described, 549–550

H

- HB-EGF. See *Heparin-binding epidermal growth factor–like growth factor (HB-EGF)*.
- Head injuries, GLN and, 518
- Heparin-binding epidermal growth factor–like growth factor (HB-EGF), in intestinal epithelial repair, regulation of, 555–556
- Hepatocyte growth factor (HGF), in intestinal epithelial repair, regulation of, 555
- HGF. See *Hepatocyte growth factor (HGF)*.
- Hyperglycemia, GLN and, 518
- Hypoxia, cytopathic, microvascular dysfunction vs., mitochondrial dysfunction in sepsis and, 571

I

- IGF-1. See *Insulin-like growth factor 1 (IGF-1)*.
- Immune function, GLN in, 517–518
- Immunosuppression, after major surgery, **491–500**
- Infection(s), after major surgery, **491–500**
- Inflammation, MODS due to, 515–516
- Inflammatory response, GLN and, 517
- Insulin resistance, GLN in, 518
- Insulin-like growth factor 1 (IGF-1), in intestinal epithelial repair, regulation of, 553–554

K

- Keratinocyte growth factor (KGF), in intestinal epithelial repair, regulation of, 554–555
- KGF. See *Keratinocyte growth factor (KGF)*.

L

Laparoscopy, ERAS and, 537–538

M

MDSCs. See *Myeloid-derived suppressor cells (MDSCs)*.

Microvascular dysfunction, cytopathic hypoxia vs., mitochondrial dysfunction in sepsis and, 571

Mitochondrial dysfunction, in sepsis, **567–573**. See also *Sepsis, mitochondrial dysfunction in*.

Mitochondrial function, energy production and, 568–570

MODS. See *Multiple organ dysfunction syndrome (MODS)*.

Mucosal repair, in gastrointestinal tract, 550–551

Multiple organ dysfunction syndrome (MODS), sepsis and inflammation and, 515–516

Myeloid cells, after PI express arginase 1 and deplete arginine, 495–496

Myeloid-derived suppressor cells (MDSCs), in overcoming arginine depletion, 496–497

N

Nitric oxide (NO), production of, arginine deficiency effects on, 493

Nutritional therapy

after ICU, 434

clinical guidelines for, **451–466**

of SCCM/A.S.P.E.N., 452–460

fish oil safety, 457–458

patient outcome–related, 460

permissive underfeeding in morbidly obese critically ill patient, 453–455

pharmakonutrition formulas, 456–457

protocols for gastric residual volumes effects on EN tolerance, 455

reliance on EBM and PRCTs, 460–462

supplemental PN, 458–460

critical care

after surgery, NIL per OS, 435–436

early and adequate, 435

evolutionary role of, **443–450**

acute phase in, 445

established phase in, 445

recovery phase in, 445–446

therapeutic implications of, 447–448

future of, **433–441**

pharmakonutrition, 436–437

O

Obesity, in critically ill patients, nutritional therapy in, SCCM/A.S.P.E.N. guidelines for, 453–455

Omega-3 fatty acids

described, 501–502

enteral, in critical illness, 504–507

in parenteral nutrition, 507–509

mechanisms of action of, 502–504
Oxygen, mitochondrial dysfunction in sepsis and, 571

P

Parenteral nutrition (PN)

in critical illness

future of, 474–477

historical background of, 468–469

mortality associated with, 472–474

outcome effects of, **467–480**

reconsideration of use of, reasons for, 469–474

timing of, impact on clinical outcome, 474

omega-3 fatty acids in, 507–509

supplemental, SCCM/A.S.P.E.N. guidelines for, 458–460

total, historical background of, 467. See also *Parenteral nutrition (PN)*.

PDH dysfunction. See *Pyruvate dehydrogenase (PDH) dysfunction*.

Pharmaconutrition, 436–437

Pharmaconutrition formulas, SCCM/A.S.P.E.N. guidelines for, 456–457

Physical injury(ies) (PIs)

arginine deficiency after, 492

infection after, **491–500**

PIs. See *Physical injury(ies) (PIs)*.

PN. See *Parenteral nutrition (PN)*.

Pneumonia(s), EN after obtaining high volume of GRV and, 486–487

PRCTs. See *Prospective randomized controlled trials (PRCTs)*.

Prospective randomized controlled trials (PRCTs), SCCM/A.S.P.E.N. guidelines

reliance on, 460–462

Pyruvate dehydrogenase (PDH) dysfunction, mitochondrial dysfunction in sepsis
and, 572

R

Recovery, after surgery, enhanced, **527–547**. See also *Enhanced recovery after
surgery (ERAS)*.

Resuscitation, in sepsis, 573

S

SCCM/A.S.P.E.N. guidelines. See *Society of Critical Care Medicine (SCCM)/American
Society for Parenteral and Enteral Nutrition (A.S.P.E.N) guidelines*.

Sepsis

mitochondrial dysfunction in, **567–573**

ATP production and, 572–573

described, 567–568

microvascular dysfunction vs. cytopathic hypoxia, 571–572

oxygen use and ATP dynamics, 571

PDH dysfunction and, 572

MODS due to, 515–516

mortality associated with, 515, 567

resuscitation in, 573

severe, hospitalization for, 515

Society of Critical Care Medicine (SCCM)/American Society for Parenteral and Enteral Nutrition (A.S.P.E.N) guidelines, derivation of, 452–460

Surgical care, improving, future of, **527–547**. See also *Enhanced recovery after surgery (ERAS)*.

T

T lymphocyte(s), function of, arginine deficiency effects on, 494–495

TFF. See *Trefoil factor family (TFF)*.

Total parenteral nutrition (TPN). See also *Parenteral nutrition (PN)*.

historical background of, 467

TPN. See *Total parenteral nutrition (TPN)*.

Trefoil factor family (TFF), in intestinal epithelial repair, regulation of, 556–557